Literature DB >> 26547319

Spinal and Bulbar Muscular Atrophy Overview.

Kenneth H Fischbeck1.   

Abstract

Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by an expanded repeat in the androgen receptor gene. The mutant protein is toxic to motor neurons and muscle. The toxicity is ligand-dependent and likely involves aberrant interaction of the mutant androgen receptor with other nuclear factors leading to transcriptional dysregulation. Various therapeutic strategies have been effective in transgenic animal models, and the challenge now is to translate these strategies into safe and effective treatment in patients.

Entities:  

Keywords:  Androgen receptor; Polyglutamine; Spinal and bulbar muscular atrophy

Mesh:

Substances:

Year:  2015        PMID: 26547319      PMCID: PMC5094812          DOI: 10.1007/s12031-015-0674-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  27 in total

1.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.

Authors:  A R La Spada; E M Wilson; D B Lubahn; A E Harding; K H Fischbeck
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

2.  Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients.

Authors:  Christopher Grunseich; Kristen Zukosky; Ilona R Kats; Laboni Ghosh; George G Harmison; Laura C Bott; Carlo Rinaldi; Ke-lian Chen; Guibin Chen; Manfred Boehm; Kenneth H Fischbeck
Journal:  Neurobiol Dis       Date:  2014-06-09       Impact factor: 5.996

3.  Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.

Authors:  Makoto Minamiyama; Masahisa Katsuno; Hiroaki Adachi; Hideki Doi; Naohide Kondo; Madoka Iida; Shinsuke Ishigaki; Yusuke Fujioka; Shinjiro Matsumoto; Yu Miyazaki; Fumiaki Tanaka; Hiroki Kurihara; Gen Sobue
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

4.  Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Satya L Reddy; Diane E Merry; Hiroaki Adachi; Masahisa Katsuno; Gen Sobue; Diane M Robins; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2013-10-22       Impact factor: 6.150

5.  Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

Authors:  Lindsay E Fernández-Rhodes; Angela D Kokkinis; Michelle J White; Charlotte A Watts; Sungyoung Auh; Neal O Jeffries; Joseph A Shrader; Tanya J Lehky; Li Li; Jennifer E Ryder; Ellen W Levy; Beth I Solomon; Michael O Harris-Love; Alison La Pean; Alice B Schindler; Cheunju Chen; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2011-01-06       Impact factor: 44.182

6.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Ichiro Yabe; Hidenao Sasaki; Masashi Aoki; Mitsuya Morita; Imaharu Nakano; Kazuaki Kanai; Shoichi Ito; Kinya Ishikawa; Hidehiro Mizusawa; Tomotaka Yamamoto; Shoji Tsuji; Kazuko Hasegawa; Takayoshi Shimohata; Masatoyo Nishizawa; Hiroaki Miyajima; Fumio Kanda; Yasuhiro Watanabe; Kenji Nakashima; Akira Tsujino; Taro Yamashita; Makoto Uchino; Yasushi Fujimoto; Fumiaki Tanaka; Gen Sobue
Journal:  Lancet Neurol       Date:  2010-08-04       Impact factor: 44.182

7.  Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors.

Authors:  Madoka Iida; Masahisa Katsuno; Hideaki Nakatsuji; Hiroaki Adachi; Naohide Kondo; Yu Miyazaki; Genki Tohnai; Kensuke Ikenaka; Hirohisa Watanabe; Masahiko Yamamoto; Ken Kishida; Gen Sobue
Journal:  Hum Mol Genet       Date:  2014-08-28       Impact factor: 6.150

8.  Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy.

Authors:  Erica S Chevalier-Larsen; Christopher J O'Brien; Huiyi Wang; Shannon C Jenkins; Latia Holder; Andrew P Lieberman; Diane E Merry
Journal:  J Neurosci       Date:  2004-05-19       Impact factor: 6.167

9.  Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.

Authors:  Haruhiko Banno; Masahisa Katsuno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Noriaki Suga; Motoko Takamori; Mizuki Ito; Tomohiko Nakamura; Koji Matsuo; Shinichi Yamada; Yumiko Oki; Hiroaki Adachi; Makoto Minamiyama; Masahiro Waza; Naoki Atsuta; Hirohisa Watanabe; Yasushi Fujimoto; Tsutomu Nakashima; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

10.  Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Carlo Rinaldi; Laura C Bott; Ke-lian Chen; George G Harmison; Masahisa Katsuno; Gen Sobue; Maria Pennuto; Kenneth H Fischbeck
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

View more
  8 in total

1.  Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02-13       Impact factor: 3.444

2.  Using genetic testing to diagnose Kennedy's disease: a case report and literature review.

Authors:  Jie Chen; Xie Long; Yan Han
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy.

Authors:  Angela Rosenbohm; Susanne Hirsch; Alexander E Volk; Torsten Grehl; Julian Grosskreutz; Frank Hanisch; Andreas Herrmann; Katja Kollewe; Wolfram Kress; Thomas Meyer; Susanne Petri; Johannes Prudlo; Carsten Wessig; Hans-Peter Müller; Jens Dreyhaupt; Jochen Weishaupt; Christian Kubisch; Jan Kassubek; Patrick Weydt; Albert C Ludolph
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

Review 4.  RBD and Neurodegenerative Diseases.

Authors:  Haiyang Jiang; Jinsha Huang; Yan Shen; Shiyi Guo; Luxi Wang; Chao Han; Ling Liu; Kai Ma; Yun Xia; Jie Li; Xiaoyun Xu; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

Review 5.  Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.

Authors:  Marianthi Breza; Georgios Koutsis
Journal:  J Neurol       Date:  2018-07-13       Impact factor: 4.849

6.  X-linked spinal and bulbar muscular atrophy (Kennedy's disease): the first case described in the Brazilian Amazon.

Authors:  Camila Nascimento Alves; Tiago Kiyoshi Kitabayashi Braga; Danusa Neves Somensi; Bruno Sérgio Vilhena do Nascimento; José Antônio Santos de Lima; Satomi Fujihara
Journal:  Einstein (Sao Paulo)       Date:  2018-06-07

7.  DNA methylation inhibitor attenuates polyglutamine-induced neurodegeneration by regulating Hes5.

Authors:  Naohide Kondo; Genki Tohnai; Kentaro Sahashi; Madoka Iida; Mayumi Kataoka; Hideaki Nakatsuji; Yutaka Tsutsumi; Atsushi Hashizume; Hiroaki Adachi; Haruki Koike; Keiko Shinjo; Yutaka Kondo; Gen Sobue; Masahisa Katsuno
Journal:  EMBO Mol Med       Date:  2019-05       Impact factor: 12.137

8.  Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy.

Authors:  Madoka Iida; Kentaro Sahashi; Naohide Kondo; Hideaki Nakatsuji; Genki Tohnai; Yutaka Tsutsumi; Seiya Noda; Ayuka Murakami; Kazunari Onodera; Yohei Okada; Masahiro Nakatochi; Yuka Tsukagoshi Okabe; Shinobu Shimizu; Masaaki Mizuno; Hiroaki Adachi; Hideyuki Okano; Gen Sobue; Masahisa Katsuno
Journal:  Nat Commun       Date:  2019-09-19       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.